Recursion Pharmaceuticals reported mixed Q2 2026 results, with revenue falling to $7.67 million from $19.22 million a year earlier. The company made significant progress in its AI-driven drug ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results